您的购物车当前为空
TM5441 是口服生物可利用的纤溶酶原激活物抑制剂-1 抑制剂,抑制多个癌症细胞系的 IC50值在 13.9 到 51.1 μM。它诱导几种人类癌症细胞的内在调亡,减弱 Nω-硝基-1-精氨酸甲酯诱导的心脏高血压和血管衰老。

TM5441 是口服生物可利用的纤溶酶原激活物抑制剂-1 抑制剂,抑制多个癌症细胞系的 IC50值在 13.9 到 51.1 μM。它诱导几种人类癌症细胞的内在调亡,减弱 Nω-硝基-1-精氨酸甲酯诱导的心脏高血压和血管衰老。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 362 | 现货 | |
| 2 mg | ¥ 518 | 现货 | |
| 5 mg | ¥ 815 | 现货 | |
| 10 mg | ¥ 1,230 | 现货 | |
| 25 mg | ¥ 2,660 | 现货 | |
| 50 mg | ¥ 3,930 | 现货 | |
| 100 mg | ¥ 5,730 | 现货 | |
| 500 mg | ¥ 11,800 | 待询 |
TM5441 相关产品
| 产品描述 | TM5441 is an orally bioavailable fibrinogen activator inhibitor-1 inhibitor that inhibits several cancer cell lines with IC50 values ranging from 13.9 to 51.1 μM.It induces intrinsic cell death in several human cancer cells and attenuates Nω-nitro-1-arginine methyl ester-induced cardiac hypertension and vascular senescence. |
| 靶点活性 | Tumor cells:9.7~60.3 μM |
| 体外活性 | 方法:使用TM5441(1-100μM)研究 HT1080、HCT116、Daoy、MDA-MB-231 和 Jurkat细胞的存活率。 |
| 体内活性 | 方法:高脂饮食(HFD)喂养的C57BL/6J小鼠每天用20mg/kg的TM5441处理,研究TM5441(一种缺乏出血风险的口服 PAI-1 抑制剂)对HFD诱导的NAFLD的影响。 |
| 激酶实验 | TM5441 is dissolved with DMSO at a stock concentration of 50 mM.HT1080, HCT116, Daoy, MDA-MB-231 and Jurkat cells are treated with 0-100 μM TM5441 for 48 hours at 37°C. Cell viability is measured by MTT assay. |
| 动物实验 | TM5441 is prepared in 0.5% carboxymethyl cellulose.Mice: TM5275 at 50 mg/kg/day and TM5441 at 10 mg/kg/day were orally administered in control and diabetic mice for 16 weeks. Mice were monitored at least once a day. At the end, blood is collected for measurement of plasma glucose and creatinine, urine for protein measurement, and kidneys for immunohistochemical analysis. |
| 分子量 | 428.82 |
| 分子式 | C21H17ClN2O6 |
| CAS No. | 1190221-43-2 |
| Smiles | OC(=O)c1cc(Cl)ccc1NC(=O)COCC(=O)Nc1cccc(c1)-c1ccoc1 |
| 密度 | 1.451 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| 溶解度信息 | DMSO: 5.67 mg/mL (13.22 mM), Sonication is recommended. | ||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.33 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
评论内容